162 related articles for article (PubMed ID: 23796863)
1. Anti-HBV treatment induces novel reverse transcriptase mutations with reflective effect on HBV S antigen.
Cento V; Van Hemert F; Neumann-Fraune M; Mirabelli C; Di Maio VC; Salpini R; Bertoli A; Micheli V; Gubertini G; Romano S; Visca M; De Sanctis GM; Berkhout B; Marino N; Mazzotta F; Cappiello G; Spanò A; Sarrecchia C; Ceccherini-Silberstein F; Andreoni M; Angelico M; Verheyen J; Perno CF; Svicher V
J Infect; 2013 Oct; 67(4):303-12. PubMed ID: 23796863
[TBL] [Abstract][Full Text] [Related]
2. High frequency of complex mutational patterns in lamivudine resistant hepatitis B virus isolates.
Neumann-Fraune M; Beggel B; Pfister H; Kaiser R; Verheyen J
J Med Virol; 2013 May; 85(5):775-9. PubMed ID: 23408582
[TBL] [Abstract][Full Text] [Related]
3. In vitro susceptibility of lamivudine-resistant hepatitis B virus to adefovir and tenofovir.
Lada O; Benhamou Y; Cahour A; Katlama C; Poynard T; Thibault V
Antivir Ther; 2004 Jun; 9(3):353-63. PubMed ID: 15259898
[TBL] [Abstract][Full Text] [Related]
4. Hepatitis B e antigen-suppressing mutations enhance the replication efficiency of adefovir-resistant hepatitis B virus strains.
Herbers U; Amini-Bavil-Olyaee S; Mueller A; Luedde T; Trautwein C; Tacke F
J Viral Hepat; 2013 Feb; 20(2):141-8. PubMed ID: 23301549
[TBL] [Abstract][Full Text] [Related]
5. Four-year study of lamivudine and adefovir combination therapy in lamivudine-resistant hepatitis B patients: influence of hepatitis B virus genotype and resistance mutation pattern.
Inoue J; Ueno Y; Wakui Y; Niitsuma H; Fukushima K; Yamagiwa Y; Shiina M; Kondo Y; Kakazu E; Tamai K; Obara N; Iwasaki T; Shimosegawa T
J Viral Hepat; 2011 Mar; 18(3):206-15. PubMed ID: 20367795
[TBL] [Abstract][Full Text] [Related]
6. [Clinical characteristics and effect of secondary individualized therapy in chronic hepatitis B patients infected with the rtA181 mutation hepatitis B virus].
Ji FZ; Wang L; Yang BH; Zhao JJ; Liu F; Xue Y; Li T
Zhonghua Gan Zang Bing Za Zhi; 2012 Apr; 20(4):280-4. PubMed ID: 22964149
[TBL] [Abstract][Full Text] [Related]
7. Changes in viral loads of lamivudine-resistant mutants and evolution of HBV sequences during adefovir dipivoxil therapy.
Suzuki F; Kumada H; Nakamura H
J Med Virol; 2006 Aug; 78(8):1025-34. PubMed ID: 16789011
[TBL] [Abstract][Full Text] [Related]
8. Impact of hepatitis B virus rtA181V/T mutants on hepatitis B treatment failure.
Villet S; Pichoud C; Billioud G; Barraud L; Durantel S; Trépo C; Zoulim F
J Hepatol; 2008 May; 48(5):747-55. PubMed ID: 18331765
[TBL] [Abstract][Full Text] [Related]
9. Hepatitis B virus genetic diversity.
Echevarría JM; Avellón A
J Med Virol; 2006; 78 Suppl 1():S36-42. PubMed ID: 16622876
[TBL] [Abstract][Full Text] [Related]
10. Adefovir dipivoxil resistance patterns in patients with lamivudine-resistant chronic hepatitis B.
Santantonio T; Fasano M; Durantel S; Barraud L; Heichen M; Guastadisegni A; Pastore G; Zoulim F
Antivir Ther; 2009; 14(4):557-65. PubMed ID: 19578241
[TBL] [Abstract][Full Text] [Related]
11. Detection of rtN236T and rtA181V/T mutations associated with resistance to adefovir dipivoxil in samples from patients with chronic hepatitis B virus infection by the INNO-LiPA HBV DR line probe assay (version 2).
Osiowy C; Villeneuve JP; Heathcote EJ; Giles E; Borlang J
J Clin Microbiol; 2006 Jun; 44(6):1994-7. PubMed ID: 16757589
[TBL] [Abstract][Full Text] [Related]
12. Evidence of long-term suppression of hepatitis B virus DNA by tenofovir as rescue treatment in patients coinfected by HIV.
Quiros-Roldan E; Calabresi A; Lapadula G; Tirelli V; Costarelli S; Cologni G; Zaltron S; Puoti M; Carosi G; Torti C
Antivir Ther; 2008; 13(3):341-8. PubMed ID: 18572746
[TBL] [Abstract][Full Text] [Related]
13. Variability of reverse transcriptase and overlapping S gene in hepatitis B virus isolates from untreated and lamivudine-resistant chronic hepatitis B patients.
Pollicino T; Isgrò G; Di Stefano R; Ferraro D; Maimone S; Brancatelli S; Squadrito G; Di Marco V; Craxì A; Raimondo G
Antivir Ther; 2009; 14(5):649-54. PubMed ID: 19704167
[TBL] [Abstract][Full Text] [Related]
14. Detection of lamivudine- or adefovir-resistant hepatitis B virus mutations by a liquid array.
Liu H; Mao R; Fan L; Xia J; Li Y; Yin Y; Li X; Zhao X; Guo H; Zhu H; Zhang Y; Kang Y; Zhang J
J Virol Methods; 2011 Jul; 175(1):1-6. PubMed ID: 21513743
[TBL] [Abstract][Full Text] [Related]
15. Susceptibility to antivirals of a human HBV strain with mutations conferring resistance to both lamivudine and adefovir.
Brunelle MN; Jacquard AC; Pichoud C; Durantel D; Carrouée-Durantel S; Villeneuve JP; Trépo C; Zoulim F
Hepatology; 2005 Jun; 41(6):1391-8. PubMed ID: 15915463
[TBL] [Abstract][Full Text] [Related]
16. Prevalence and profile of mutations associated with lamivudine therapy in Indian patients with chronic hepatitis B in the surface and polymerase genes of hepatitis B virus.
Wakil SM; Kazim SN; Khan LA; Raisuddin S; Parvez MK; Guptan RC; Thakur V; Hasnain SE; Sarin SK
J Med Virol; 2002 Nov; 68(3):311-8. PubMed ID: 12226816
[TBL] [Abstract][Full Text] [Related]
17. Profile of HBV antiviral resistance mutations with distinct evolutionary pathways against nucleoside/nucleotide analogue treatment among Chinese chronic hepatitis B patients.
Yang JX; Liu BM; Li XG; Yan CH; Xu J; Sun XW; Wang YH; Jiao XJ; Yan L; Dong JP; Hou CS; Abuduheilili X; Li T; Zhuang H
Antivir Ther; 2010; 15(8):1171-8. PubMed ID: 21149924
[TBL] [Abstract][Full Text] [Related]
18. rtE218G, a novel hepatitis B virus mutation with resistance to adefovir dipivoxil in patients with chronic hepatitis B.
Liu LJ; Wang JH; Du SC; Tian JH; Yang RF; Wei L
J Viral Hepat; 2010 Mar; 17 Suppl 1():66-72. PubMed ID: 20586936
[TBL] [Abstract][Full Text] [Related]
19. Factors influencing inadequate or suboptimal response to adefovir with or without genotypic resistance.
Zhou X; Kuang X; Fan K; Zhang C; Deng G; Wang H; Wang Y
J Med Virol; 2012 Jul; 84(7):1030-6. PubMed ID: 22585719
[TBL] [Abstract][Full Text] [Related]
20. Selection of the highly replicative and partially multidrug resistant rtS78T HBV polymerase mutation during TDF-ETV combination therapy.
Shirvani-Dastgerdi E; Winer BY; Celià-Terrassa T; Kang Y; Tabernero D; Yagmur E; Rodríguez-Frías F; Gregori J; Luedde T; Trautwein C; Ploss A; Tacke F
J Hepatol; 2017 Aug; 67(2):246-254. PubMed ID: 28392234
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
